Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 242-833-4 | CAS number: 19139-31-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics, other
- Remarks:
- assessment of toxicokinetic behavior
- Type of information:
- other: In accordance with REACH Annex VIII (8.8) an assessment of toxicokinetic behavior has been conducted to the extent that can be derived from the relevant available information.
- Adequacy of study:
- key study
- Study period:
- The assessment was conducted in January 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Relevant studies were reviewed with a view to fulfilling the requirements of Annex VIII (8.8).
- Objective of study:
- toxicokinetics
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- In accordance with REACH Annex VIII (8.8) an assessment of toxicokinetic behaviour has been conducted to the extent that can be derived from the relevant available information. The assessment is based on the Guidance on information requirements and chemical safety assessment R.7c: Endpoint specific guidance (ECHA, June 2017)
- GLP compliance:
- no
- Remarks:
- Not relevant for assessment
- Conclusions:
- The available information suggests that absorption of the test substance from the gastrointestinal tract and absorption via the skin will be limited. Widespread distribution of any absorbed substance is not anticipated. Any substance absorbed may have some potential to accumulate in fatty tissues. Biliary excretion may well be the significant route of excretion. There is no evidence to suggest that the test substance may be metabolised.
Reference
Toxicokinetic Behaviour:
The substance is a powder with a molecular weight of 284.391 g/mol.
The substance has a low vapour pressure (3 x 10-2 Pa at 25°C), low melting point (10°C), is not highly flammable and is not an explosive or oxidising. The substance is considered to be of low-volatility and therefore inhalation is not a significant route of exposure.
The substance has a high log octanol/water partition coefficient (Log Pow > 6) and low water solubility (0.15 mg/L). Hydrolysis study identifies t1/2 to be 16-34 days between pH 4 and 7 at 25°C.
There were no signs of toxicity in acute oral and dermal toxicity studies.
A 28-day repeated dose toxicity study, reproductive toxicity screening study (and associated 14-day range finding study) showed no significant evidence of absorption.
The substance is not a skin irritant or skin sensitiser.
The substance was non-mutagenic in bacteria in either the absence or presence of an auxiliary metabolising system, and was non-mutagenic in mammalian cells in vitro (L5178Y mouse lymphoma cell line) in either the absence or presence of an auxiliary metabolising system. However in mammalian cells in vitro (human lymphocytes) the test item was determined to be clastogenic. The response was due to mainly break-type aberrations which may be induced by a cytotoxic mechanism rather than a genotoxic mechanism and, therefore, have reduced biological relevance. In the MLA study however, no genotoxic activity was recorded in the any of the exposure conditions. Since in an MLA study the test cultures undergo a 48-hour expression period prior to plating out for viability and expression of mutagenicity, during this expression period any mutagenic response that induces high levels of toxicity in the cells results in cell death due to lowered viability. In the chromosome aberration data, the lack of an expression period results in the presence of mutagenic events that would most likely be non-viable if the cultures were maintained for a greater period of time.
Absorption:
Inhalation is not considered to be a significant route of exposure based on the substance being non-volatile.
The molecular weight of the substance does not preclude absorption from the gastrointestinal tract following oral ingestion. However, the log Pow (>6) and low water solubility (0.15 mg/L) of the substance suggest that absorption would be limited from the gastrointestinal tract following oral ingestion. Any absorption that occurs for this substance may be by micellular solubilisation.
Limited absorption from the gastrointestinal tract following oral ingestion is supported by the results from oral toxicity studies. An acute oral toxicity study showed no evidence of systemic toxicity. In an oral repeated dose toxicity study (OECD 422) there was no significant evidence of absorption. The only effects observed in the study were determined not to be treatment related, or the magnitude of these differences from controls were minimal and there were no corroborative microscopic findings, and the effects were considered not to be of toxicological importance.
The results from a toxicity reproductive toxicity screening study (and 14-day range finding study) also show limited evidence of absorption.
The log Pow and low water solubility of the substance suggest that dermal absorption will be low. This is supported by the results of an in-vivo skin irritation study and skin sensitisation studies, which showed no evidence of systemic toxicity.
The substance is not a skin irritant so significant damage to the skin surface should not occur to enhance penetration.
The results of the available acute and repeated dose toxicity studies show no significant evidence of toxicity and there is little to confirm that there has been significant absorption of the substance; or the substance is not inherently toxic.
Distribution:
There is no significant evidence to suggest widespread distribution of the substance will occur. This is supported by the low water solubility of the substance.
Significant systemic distribution was not evident from the repeated dose toxicity studies (28-day toxicity study and reproductive toxicity screening study).
The lack of skin sensitization response would suggest the substance does not bind to circulatory proteins.
The partition coefficient (Log Pow >6) would suggest the substance has some limited affinity to accumulate in fatty tissues.
Metabolism:
The results of the repeated dose toxicity study did not show evidence to indicate any substance influenced hepatic metabolism.
The results of the genotoxicity assays have shown that genotoxicity is neither enhanced or diminished in the presence of a metabolising system.
Excretion:
There is no evidence to indicate the route of excretion but poorly water-soluble products are not favourable for urinary excretion and therefore biliary excretion may well be a significant route for this substance. Any substance that is not absorbed will be excreted in the faeces.
Description of key information
The available information suggests that absorption of the test substance from the gastrointestinal tract and absorption via the skin will be limited. Widespread distribution of any absorbed substance is not anticipated. Any substance absorbed may have some potential to accumulate in fatty tissues. Biliary excretion may well be the significant route of excretion. There is no evidence to suggest that the test substance may be metabolised.
Key value for chemical safety assessment
- Bioaccumulation potential:
- low bioaccumulation potential
Additional information
Absorption:
Inhalation is not considered to be a significant route of exposure based on the substance being non-volatile.
The molecular weight of the substance does not preclude absorption from the gastrointestinal tract following oral ingestion. However, the log Pow (>6) and low water solubility (0.15 mg/L) of the substance suggest that absorption would be limited from the gastrointestinal tract following oral ingestion. Any absorption that occurs for this substance may be by micellular solubilisation.
Limited absorption from the gastrointestinal tract following oral ingestion is supported by the results from oral toxicity studies. An acute oral toxicity study showed no evidence of systemic toxicity. In an oral repeated dose toxicity study (OECD 422) there was no significant evidence of absorption. The only effects observed in the study were determined not to be treatment related, or the magnitude of these differences from controls were minimal and there were no corroborative microscopic findings, and the effects were considered not to be of toxicological importance.
The results from a toxicity reproductive toxicity screening study (and 14-day range finding study) also show limited evidence of absorption.
The log Pow and low water solubility of the substance suggest that dermal absorption will be low. This is supported by the results of an in-vivo skin irritation study and skin sensitisation studies, which showed no evidence of systemic toxicity.
The substance is not a skin irritant so significant damage to the skin surface should not occur to enhance penetration.
The results of the available acute and repeated dose toxicity studies show no significant evidence of toxicity and there is little to confirm that there has been significant absorption of the substance; or the substance is not inherently toxic.
Distribution:
There is no significant evidence to suggest widespread distribution of the substance will occur. This is supported by the low water solubility of the substance.
Significant systemic distribution was not evident from the repeated dose toxicity studies (28-day toxicity study and reproductive toxicity screening study).
The lack of skin sensitization response would suggest the substance does not bind to circulatory proteins.
The partition coefficient (Log Pow >6) would suggest the substance has some limited affinity to accumulate in fatty tissues.
Metabolism:
The results of the repeated dose toxicity study did not show evidence to indicate any substance influenced hepatic metabolism.
The results of the genotoxicity assays have shown that genotoxicity is neither enhanced or diminished in the presence of a metabolising system.
Excretion:
There is no evidence to indicate the route of excretion but poorly water-soluble products are not favourable for urinary excretion and therefore biliary excretion may well be a significant route for this substance. Any substance that is not absorbed will be excreted in the faeces.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.